Co-founder and member of the board of directors Hong-hoi Ting, D.Phil. Appointed Chief Strategy Officer
James McCarterPh.D. Appointed Vice President, Head of Radioisotope Technology Research
William Diamonddoctorate, Carl Rossdoctorate and Herbert MoorePh.D. Join the Radioisotope Technology Advisory Board
SHANGHAI and BRUSSELS, August 10, 2022 /PRNewswire/ — Full-Life Technologies Co., Ltd. (“Full-Life”) today announced two key appointments to its Radioisotope Technology leadership team and the creation of a Radioisotope Technology Advisory Board that furthers the expertise of society in radioisotope technology. Full-Life Co-Founder and Board Member Joins Company’s Leadership Team Hong-hoi Ting, D.Phil. as Chief Strategy Officer, and James McCarterdoctorate as vice-president, responsible for research on radioisotope technology.
The company’s newly formed Radioisotope Technology Advisory Board is comprised of well-known industry leaders in the field of radioisotope technology. The founding members of the advisory board include: William Diamonddoctorateformer Senior Scientist at Atomic Energy Canada; Carl Rossdoctorateformer physicist at National Research Council of Canada; and Herbert Mooredoctorateformer director of research at New England DuPont.
“The appointments of Dr. Ting and Dr. McCarter provide Full-Life with a great depth and breadth of commercial and technical expertise in radioisotopes and radiopharmaceutical technology as we progress and expand our strong pipeline,” said Philippe van Put, CEO of Full-Life Europe. “Dr. Ting, who helped set the direction of Full-Life as co-founder and board member, has an exceptional track record in building and leading the growth of radiation therapy and healthcare businesses. Dr. McCarter brings over 18 years of experience as a leader in engineering physics, particle accelerators and radioisotope technology.”
Mr Van Put continued, “The distinguished experts on our Radioisotope Technology Advisory Board have a wealth of experience that spans the discovery, development and production of radioisotope technology and reflects our ambition to build a fully integrated for the development of next-generation targeted radiotherapy. Their expertise and knowledge will help us fulfill the company’s mission.”
Dr. Ting is a scientist, entrepreneur and angel investor. Prior to joining Full-Life, he was the first Chinese Managing Director of Amersham International Plc. During his tenure at Amersham, he launched a very successful joint venture with China Isotope Corporation, CICAM, one of the largest smoke detector alpha sheet manufacturers in the world. He was instrumental in the launch of Amersham Kexing Pharmaceutical (Shanghai), a joint venture with the CAS Shanghai Institute of Nuclear Research, for the cyclotron production of medical radioisotopes. Additionally, he was CEO and co-founder of Nanomab Technology, Oxford Vacmedix and Biovue Technology Ltd. and was co-founder of Genemedix Plc., a biotechnology company co-listed on the main boards of the London Stock Exchange. (LSE) and Shanghai Stock Exchange (SSE) prior to its acquisition by Reliance Group. He has also held consulting positions with Westinghouse Electric, Johnson & Johnson, GE Healthcare, CGN Nuclear Technology and ITM GmbH. Dr. Ting earned his doctorate in philosophy. of Oxford University and held a permanent position as a senior academic researcher under the direction of Professor by JE Baldwin group before pursuing a career in the industry.
Dr. McCarter’s passion is leading multidisciplinary teams to solve complex technical problems. His technical expertise covers systems engineering and integration, electron accelerators, electron sources, controls and diagnostics, and high power targets. Prior to joining Full-Life, he held technical and research leadership positions at NorthStar Medical Radioisotopes, LLC, Niowave, Inc, and the University of Virginia. Most notably, he was the irradiation team manager at NorthStar Medical Radioisotopes, LLC, where he was also the technical lead for their multi-million dollar program to develop and build an accelerator-based facility for the production of Mo-99. Dr. McCarter earned his Ph.D. degree in engineering physics from University of Virginiawith research conducted at the Thomas Jefferson National Accelerator Facility.
Radioisotope Technology Advisory Board Launched with three renowned scientists
dr. William Diamond, Ph.D., has extensive experience in physics, applied physics and nuclear reactor engineering and is a leading expert in the physics of ion source plasmas and high voltage vacuum insulation. He has held senior scientific positions at Atomic Energy of Canada Limited (AECL), Jefferson Laboratories, and Schlumberger-Doll Research until his retirement in 2010. Since then he has held consulting positions at Canadian Light Source Incorporated (CLSI) and Queen’s University on accelerator design and licensing projects . He has received five “Discovery Awards”, AECL’s highest research honor and he is named on five patents (lead author of two) and author of numerous published scientific papers and numerous unpublished proprietary reports both at Schlumberger -Doll Research and AECL. He holds a doctorate. in nuclear physics since University of Toronto.
dr. Carl Ross, Ph.D., is a leading expert in photonuclear reactions, ionizing radiation and radiation standards. His career at National Research Council of Canada spanned over 40 years, during which time he held several positions, including Senior Research Officer and Ionizing Radiation Standards Group Leader. In 2011, Dr. Ross and his colleagues received an NRC Outstanding Achievement Award for their work on the production of Tc-99m. He has served on the scientific committees of the International Commission on Radiation Units and Measurements (ICRU) and the International Atomic Energy Agency (IAEA). Since retiring in 2014, he has continued his research in radiation physics and medical isotopes. Dr. Ross earned his Ph.D. in nuclear physics McMaster University, hamilton(Ontario, Canada), in 1973.
dr. Herbert Moore, Ph.D., is an expert in isotope production and photonuclear reactions, and has extensive experience in the field of medical isotopes. He began his career in radiopharmaceutical research at Medi+Physics (MPI) where he participated in several projects, contributed to four clinical trials and FDA approvals. Dr. Moore also worked at New England Du Pont where he improved the production of several medical isotopes including Ga-67, Ga-68, In-111, Tl-201 and Mo-99 (Tc-99m). After retiring from Du Pont, he focused on photonuclear reactions and isotope production, as well as the production of selected alpha emitters with therapeutic or palliative potential. Dr. Moore earned his BSc in Chemistry and his Ph.D. in Nuclear Engineering with strong minors in Mathematics and Physics of University of California at Berkeley.
About Full-Life Technologies
Full-Life Technologies Limited (“Full-Life”) is a fully integrated, global radiation therapy company operating in Europe and China. We seek to own the entire value chain for research and development, production and commercialization of radioligands in order to have a clinical impact for patients. We plan to tackle fundamental issues affecting today’s radiopharmaceuticals through innovative research that targets tomorrow’s treatments. We are made up of a dynamic team of entrepreneurs and scientists with a proven track record in life sciences as well as radioisotope research and clinical development.
Follow us: www.full-life.com
SOURCE Full-Life Technologies Limited